Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer
- 11 June 2020
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 147 (11) , 3177-3188
Abstract
Fluoropyrimidine (FP) plus platinum chemotherapy has been recently established as a second‐line (L2) preferred option in advanced biliary tract cancer (aBTC) (ABC‐06 phase III trial). However, the overall survival (OS) benefit was limited and comparison with FP monotherapy was not available. Our aim was to assess the OS of patients treated with a FP monotherapy compared to a doublet with irinotecan or platinum in L2. We performed a retrospective analysis of two large multicenter prospective cohorts: a French cohort (28 centers) and an Italian cohort (9 centers). All consecutive patients with aBTC receiving FP‐based L2 after gemcitabine plus cisplatin/gemcitabine plus oxaliplatin L1 between 2003 and 2016 were included. A subgroup analysis according to performance status (PS) and an exploratory analysis according to platinum sensitivity in L1 were planned. In the French cohort (n = 351), no significant OS difference was observed between the FP monotherapy and doublet groups (median OS: 5.6 vs 6.8 months, P = .65). Stratification on Eastern Cooperative Oncology Group (ECOG) PS showed similar results in PS 0‐1 and 2. Median OS was not different between FP monotherapy, platinum‐ and irinotecan‐based doublets (5.6 vs 7.1 vs 6.7 months, P = .68). Similar findings were observed in the Italian cohort (n = 174) and in the sensitivity analysis in pooled cohorts (n = 525). No L2 regimen seemed superior over others in the platinum resistant/refractory or sensitive subgroups. Our results suggest that FP monotherapy is as active as FP doublets in aBTC in L2, regardless of the patient PS and country, and could be a therapeutic option in this setting.Keywords
This publication has 24 references indexed in Scilit:
- Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published dataJournal of Experimental & Clinical Cancer Research, 2015
- Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinomaCancer Chemotherapy and Pharmacology, 2015
- Second‐line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine‐platinum combination: A large multicenter study by the Association des Gastro‐Entérologues OncologuesCancer, 2015
- Second-line chemotherapy in advanced biliary cancer: a systematic reviewAnnals of Oncology, 2014
- Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancerBritish Journal of Cancer, 2014
- A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancerCancer Chemotherapy and Pharmacology, 2013
- Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabineInvestigational New Drugs, 2010
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- S-1 Monotherapy in Patients with Advanced Biliary Tract CancerOncology, 2009
- A note on quantifying follow-up in studies of failure timeControlled Clinical Trials, 1996